264 related articles for article (PubMed ID: 36763878)
41. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials.
Mahmoud AM
Curr Med Res Opin; 2023 Feb; 39(2):249-257. PubMed ID: 36239359
[TBL] [Abstract][Full Text] [Related]
43. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
44. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
45. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
46. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
[TBL] [Abstract][Full Text] [Related]
47. Olumiant
Gupta AK; Wang T; Vincent K; Abramovits W
Skinmed; 2022; 20(6):452-455. PubMed ID: 36537681
[TBL] [Abstract][Full Text] [Related]
48. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
49. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
King B; Mesinkovska N; Mirmirani P; Bruce S; Kempers S; Guttman-Yassky E; Roberts JL; McMichael A; Colavincenzo M; Hamilton C; Braman V; Cassella JV
J Am Acad Dermatol; 2022 Aug; 87(2):306-313. PubMed ID: 35364216
[TBL] [Abstract][Full Text] [Related]
50. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
Senna MM; Kwon O; Piraccini BM; Sinclair R; Ball S; Ding Y; Chen YF; Dutronc Y; King B
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3209-3220. PubMed ID: 37991697
[TBL] [Abstract][Full Text] [Related]
51. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
De Greef A; Thirion R; Ghislain PD; Baeck M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
[TBL] [Abstract][Full Text] [Related]
52. Baricitinib as the first systemic treatment for severe alopecia areata.
Kincaid CM; Arnold JD; Mesinkovska NA
Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
[TBL] [Abstract][Full Text] [Related]
55. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract][Full Text] [Related]
57. Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.
Radi G; Simonetti O; Rizzetto G; Diotallevi F; Molinelli E; Offidani A
Healthcare (Basel); 2021 Nov; 9(11):. PubMed ID: 34828623
[No Abstract] [Full Text] [Related]
58. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
[TBL] [Abstract][Full Text] [Related]
59. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
60. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
Katoh N; Ohya Y; Murota H; Ikeda M; Hu X; Ikeda K; Liu J; Sasaki T; Chu AD; Teixeira HD; Saeki H
JAAD Int; 2022 Mar; 6():27-36. PubMed ID: 34988493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
